- Dec 5, 2013
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
Phase III study PETHEMA (GEM2012MENOS65) GEM12 MENOS65 PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa...
303
- Dec 5, 2013
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
IFM2013-04 NCT01971658: Phase 3: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone...
208
- Dec 6, 2012
NCT01668719: Phase 1/2 - S1211 Bort, Dex & Lenalidomide +/- Elotuzumab High Risk NDMM SWOG 1211
SWOG 1211 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed...
140
- Dec 9, 2011
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
790
- Dec 8, 2011
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients KRd Carfilzomib is an experimental...
133
- Dec 7, 2011
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
EMN European Myeloma Network NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma...
67